BMEA · Biomea Fusion

The thesis

Biomea Fusion is more likely to lag the S&P 500 over the next three months. Its cash fell to $26.8 million at 30 September 2026 from $35.2 million at 30 June 2026, the oral GLP-1 drug BMF-650 has no partner, and the company has not completed a financing since withdrawing its September offering. The shares closed at $0.56 on 12 November 2026, and the 16 November 2026 ObesityWeek poster and any financing or partnership news settle whether that view holds.

The third-quarter report arrived on 10 November 2026, when the company also filed its Form 10-Q. Net loss was $6.2 million against $16.4 million a year earlier, research and development spending was $8.5 million against $14.4 million, and general and administrative spending was $4.4 million (BiopharmaWatch summary of the release). Biomea still projects cash into the second quarter of 2027, the same runway it gave in August. The Q2 2026 Form 10-Q carried substantial-doubt going-concern language.

The shares did not rally on the report. They closed at $0.55 on 10 November 2026, $0.61 on 11 November 2026 and $0.56 on 12 November 2026.

Bullish and bearish views on Biomea Fusion, Inc.

The bull case on Biomea Fusion, Inc. (BMEA), in brief: weight loss appeared in every cohort. The bear case: cash is short and falling.

Bull case

• Weight loss appeared in every cohort. In outpatient cohorts 1–4, mean weight reduction at Day 29 ranged from 1.5% to 3.2%, against 0.1% for pooled placebo (company press release, 13 October 2026).
• The highest-dose group lost 6.1%. The confined fifth cohort lost a mean 6.1% (6.2 kg) by Day 29 on 200 mg daily for one week, then 400 mg daily for three weeks (company press release, 13 October 2026).
• Tolerability looked clean. Biomea reported no severe or serious treatment-emergent adverse events among 40 BMF-650-treated participants. Nausea was 17.5% and vomiting 7.5% (press release summarised by AllSci, 14 October 2026).
• Spending is falling. Research and development cost was $8.5 million in the third quarter of 2026, against $14.4 million a year earlier, and the quarterly loss narrowed to $6.2 million from $16.4 million (BiopharmaWatch summary of the 10 November 2026 release). Biomea reported a third-quarter loss of $0.09 per share against a $0.21 estimate (company news, 10 November 2026).
• A partner would change the funding picture. Biomea said on 10 November 2026 that it will pursue a strategic partnership, including licensing for late-stage development and commercialisation of BMF-650. It will present the Phase I results at ObesityWeek on 16 November 2026.

Bear case

• Cash is short and falling. Cash, equivalents and restricted cash were $26.8 million at 30 September 2026, against $56.2 million at 31 December 2025 and $35.2 million at 30 June 2026 (BiopharmaWatch summary of the 10 November 2026 release; Q2 2026 Form 10-Q). Runway is guided only into the second quarter of 2027.
• The going-concern warning stands. The Q2 2026 Form 10-Q states that resources will not fund operations for twelve months past issuance. The accumulated deficit was $469.8 million at 30 June 2026.
• A financing was attempted and withdrawn. Biomea announced a public offering on 22 September 2026 and terminated it on 23 September 2026, citing market conditions; no securities were sold (Benzinga, 23 September 2026). An effective Form S-3 shelf registration allows new shares to be issued quickly.
• The placebo comparison is muddied. The two placebo participants in the confined cohort also lost weight, and Biomea said this complicates placebo-adjusted interpretation (company press release, 13 October 2026).
• BMF-650 needs more work and outside money. Biomea says further development requires longer-term toxicology studies, and it plans 13-week toxicology work before Phase II weight-loss trials (MarketBeat, 13 October 2026). No partner has been announced.
• Selling has continued after the data. The close fell from $0.83 on 14 October 2026 to $0.56 on 12 November 2026, and the shares fell 57.4% over three months (adjusted daily closes).

Price setup

The shares closed at $0.56 on 12 November 2026. That is 75.0% below the 52-week intraday high of $2.24 on 20 April 2026. The 52-week closing low is $0.55, set on 10 November 2026, two sessions earlier. The 3-month reference close was $1.32 on 14 August 2026.

The 50-day average is $1.16 and the 200-day average is $1.34, both as of the 12 November 2026 close. The shares trade well under both, and under $1.00 in every session from 5 November to 12 November 2026. Nasdaq's minimum-bid rule is breached after 30 consecutive business days of closes below $1.00, and the company would disclose a notice on Form 8-K.

The price already reflects a high chance of dilution: at $0.56 the shares trade 75.0% under their April high, with $26.8 million of cash at 30 September 2026 and no partner or completed financing announced.

Catalysts ahead

• 16 November 2026: ObesityWeek 2026 poster presenting the BMF-650 Phase I results (poster 828, National Harbor, Maryland), announced by the company on 10 November 2026. It adds detail on dose response, placebo comparison and tolerability that a prospective licensing partner would weigh.
• ~31 March 2027 (est.): COVALENT-211 topline on the 26-week HbA1c primary endpoint, guided for the first quarter of 2027. This placebo-controlled result tests icovamenib's glucose-control claim, and it falls after the guided runway of the second quarter of 2027 begins to tighten.

What would change the view

A daily close above $0.73, about 30% over the last close, would show the shares leading the S&P 500. So would a signed BMF-650 partnership or licence with an upfront payment.

What it trades with

BMEA trades on its own financing, partnership and trial news. Sentiment in the oral GLP-1 field sets the backdrop for any licensing talks over BMF-650, and risk appetite for small-cap biotech funding rounds affects whether a new offering can price.